» Articles » PMID: 30954406

Treatment Decision-making in Chronic Lymphocytic Leukaemia: Key Factors for Healthcare Professionals. PRELIC Study

Overview
Journal J Geriatr Oncol
Publisher Elsevier
Specialty Geriatrics
Date 2019 Apr 8
PMID 30954406
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse, condition that mainly afflicts older adults.

Methods: A discrete choice experiment (DCE) was conducted among haematologists and hospital pharmacists. A literature review and a focus group informed the DCE design. CLL treatment settings were defined by seven attributes: four patient/disease-related attributes (age, functional status, comorbidities, and risk of the disease) and three treatment-related attributes (efficacy [hazard ratio of progression-free survival, HR-PFS], rate of discontinuations due to adverse events and cost). A mixed-logit model was used to determine choice-based preferences. Relative importance (RI) of attributes was calculated and compared between stakeholders. Willingness-to-pay (WTP) was estimated through the DCE. Besides, nine ad-hoc questions were posed, to explore more in depth CLL treatment decision making.

Results: A total of 130 participants (72 haematologists and 58 hospital pharmacists) answered the DCE. All attributes were significant predictors of preferences (p < 0.05) in the multinomial model. Higher RI was obtained for treatment-related attributes: the highest rated being 'cost' (23.8%) followed by 'efficacy' (20.9%). Regarding patient-related attributes, the highest RI was obtained for 'age' (18.1%). No significant differences (p > 0.05) in RI between haematologists and pharmacists were found. WTP for the treatment was higher for younger CLL patients. Ad-hoc questions showed that patient age and functional status influence treatment decisions.

Conclusions: For healthcare professionals, 'cost' and 'efficacy' (treatment-related attributes) and age (patient-related attribute) are the main factors that determine CLL treatment selection at first relapse. WTP decreases as patient's age increases.

Citing Articles

Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia.

Monica M, Reczek M, Kawalec P Ther Adv Med Oncol. 2024; 16:17588359241263710.

PMID: 39091602 PMC: 11292688. DOI: 10.1177/17588359241263710.


Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia.

Fifer S, Godsell J, Opat S, Hamad N, Lasica M, Forsyth C BMC Cancer. 2024; 24(1):831.

PMID: 38992616 PMC: 11241996. DOI: 10.1186/s12885-024-12589-9.


What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment.

Laurenti L, Gaidano G, Mauro F, Molica S, Pasqualetti P, Scarfo L Hemasphere. 2022; 6(9):e771.

PMID: 36081648 PMC: 9436277. DOI: 10.1097/HS9.0000000000000771.


Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.

Fernandez O, Lazaro-Quintela M, Crespo G, de Prado D, Pinto A, Basterretxea L Front Oncol. 2022; 11:773366.

PMID: 35070976 PMC: 8777125. DOI: 10.3389/fonc.2021.773366.


A Systematic Review of Discrete Choice Experiments in Oncology Treatments.

Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R Patient. 2021; 14(6):775-790.

PMID: 33950476 DOI: 10.1007/s40271-021-00520-4.